Efficacy and Safety of Camrelizumab Combined With Irinotecan, Leucovorin and Fluorouracil (FOLFIRI) Chemotherapy and Bevacizumab Targeted Induction Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer: a Prospective, Multicenter, Single-arm Study
The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic colorectal cancer (MSS). The main questions it aims to answer are: 1. To explore the efficacy and safety of this treatment mode 2. Try to study treatment benefit the characteristics of the crowd Participants will combined with immunotherapy after chemotherapy and bevacizumab induction therapy.
• Patients voluntarily participated in the study signed the informed consent and had good compliance
• Body weight ≥40kg
• Metastatic colorectal cancer confirmed by histology and/or cytology and initially unresectable
• Microsatellite instable (MSS) or proficient Mismatch Repair (pMMR)
• Patients have at least one measurable lesion (RECIST 1.1)
• Eastern Cooperative Oncology Group Physical Status (ECOG PS) 0-1
• Expected survival ≥12 weeks
• Blood testing (not corrected with granulocyte colony-stimulating factor or other hematopoietic stimulating factor within 7 days prior to laboratory testing if not transfused within 14 days)
• Women of reproductive age had to have a serum pregnancy test with a negative result within 14 days before treatment and be willing to use a medically approved effective contraceptive during the study and for 3 months after the last dose of study medication
⁃ Age 18-75 years old (including 18 and 75 years old)